Rocket Doctor’s marketing agreement with Rick Ware Racing and FINTEKK AP is written to renew itself by default. Unless the company delivers written notice at least ten days before September 30 electing to pause the arrangement, services continue automatically through December 31 for an additional 3,000,000 shares, worth a stated US$1.5 million, issued in two tranches in November and December. The initial phase of the campaign, running June 6 through September 30, was paid for with 7,000,000 shares at a deemed price of US$0.50 each.

That default-renewal structure is the detail Vancouver-based investor Yazan Al Homsi has flagged as worth watching more closely than the racing calendar itself. A separate option, exercisable only with mutual written consent of all parties, could extend the arrangement into 2027 for up to US$5 million in additional shares — an option, not a commitment, and every tranche carries a lock-up restricting resale after issuance.

Al Homsi holds a disclosed position in Rocket Doctor through Founders Round Capital and has no board seat or operating role at the company; his reading of the deal is his own, as a shareholder assessing a contract mechanism. More of his analysis is available on his website, and his professional background is listed on his LinkedIn profile.

A public decision either way, or the absence of one as the deadline passes, is itself a data point about how Rocket Doctor is weighing the campaign’s return against the dilution it carries. Coverage of the agreement has said it will be updated once Rocket Doctor discloses which way it went.